Influence of nonalcoholic fatty liver disease on the therapeutic effect of nucleoside (acid) analogs for hepatitis B virus

Table 2 Logistic regression analysis of risk factors for partial virological response to antiviral therapy of chronic hepatitis B

Variable	Univariate analysis			Multivariate analysis model I			Multivariate analysis model II			Multivariate analysis model III
	β	OR (95%CI)	P value	β	OR (95%CI)	P value	β	OR (95%CI)	P value	β	OR (95%CI)	P value
Age (years)	-0.033	0.968 (0.949-0.986)	0.001	-0.013	0.987 (0.965-1.009)	0.253	-0.004	0.996 (0.971-1.021)	0.746	-0.003	0.997 (0.973-1.023)	0.842
HBV DNA baseline level, log10 (IU/mL)	0.183	1.201 (1.086-1.328)	< 0.001	0.017	1.017 (0.886-1.168)	0.809	0.011	1.011 (0.87-1-176)	0.884	0.008	1.008 (0.867-1.173)	0.913
Virus shedding time (months)	0.063	1.065 (1.033-1.097)	< 0.001	0.033	1.033 (1.001-1.067)	0.046	0.038	1.039 (1.002-1.078)	0.039	0.039	1.04 (1.002-1.078)	0.037
HBeAg positive (vs negative)	0.787	2.196 (1.461-3.302)	< 0.001	-0.18	0.836 (0.468-1.492)	0.544	-0.06	0.942 (0.501-1.773)	0.853	-0.083	0.92 (0.488-1.736)	0.797
HBsAg baseline level, log10 (IU/mL+1)	0.624	1.866 (1.5-2.322)	< 0.001	0.507	1.661 (1.254-2.2)	< 0.001	0.517	1.677 (1.237-2.273)	0.001	0.52	1.682 (1.239-2.282)	0.001
NAFLD (vs non-NAFLD)	0.575	1.777 (1.11-2.845)	0.017	0.583	1.792 (1.068-3.006)	0.027	0.92	2.508 (1.368-4.6)	0.003	0.9	2.459 (1.34-4.514)	0.004
APRI score	-0.069	0.934 (0.836-1.043)	0.224				-0.052	0.949 (0.853-1.056)	0.34
FIB-4 score	-0.041	0.96 (0.92-1.002)	0.061							-0.023	0.977 (0.939-1.016)	0.247

HBV DNA: Hepatitis B virus deoxyribonucleic acid; NAFLD: Nonalcoholic fatty liver disease; HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen; APRI: Aspartate aminotransferase-to-platelet ratio index; FIB-4: Fibrosis-4 index; OR: Odds ratio.